October 5, 2016New England Journal of Medicine369 citationsOpen Access
Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis
View Full Paper
Key Points
- To evaluate whether adding levosimendan to standard therapy prevents acute organ dysfunction and reduces mortality in adults with sepsis.
- Randomized clinical trial (LeoPARDS, ISRCTN12776039) evaluating the addition of levosimendan versus standard care in adult sepsis patients.
- Levosimendan was not associated with less severe organ dysfunction or lower mortality compared to standard care.
- Levosimendan was associated with a lower likelihood of successful weaning from mechanical ventilation and a higher risk of supraventricular tachyarrhythmia.
Abstract
The addition of levosimendan to standard treatment in adults with sepsis was not associated with less severe organ dysfunction or lower mortality. Levosimendan was associated with a lower likelihood of successful weaning from mechanical ventilation and a higher risk of supraventricular tachyarrhythmia. (Funded by the NIHR Efficacy and Mechanism Evaluation Programme and others; LeoPARDS Current Controlled Trials number, ISRCTN12776039 .).
Cite This Study
Gordon et al. (2016) studied this question.